ClinicalTrials.gg
TerminatedNCT00811967Updated Mar 13, 2017

Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED)

A Phase 3 interventional study of PegIntron (peginterferon alfa-2b; SCH 54031) and Rebetol (ribavirin; SCH 18908) in Hepatitis C, Chronic and Liver Cirrhosis, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-03-13.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
20 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2b · Hepatitis C, Chronic.

Enrollment
27th of 39
50 · median 99
Started
2003
with 1 other
Phase 3
22 of 40
none open now
Registered
30th of 40
by date
Lead sponsor
25 of 40
Merck Sharp & Dohme LLC

Among the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic, this one is the 27th largest by enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2003, is one of 22 in phase 3, and was the 30th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About peginterferon alfa-2b

peginterferon alfa-2b: first FDA approval 2001 (PEGINTRON), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 20 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic as a file.
02

Study summary

The objective of the study is to evaluate the superiority of treatment with PegIntron and Rebetol over no antiviral therapy (control group) in subjects with chronic hepatitis C and type C compensated cirrhosis. Subjects will be randomized in a ratio of 2:1 (Treatment Arm to Control Arm). Subjects in the Treatment Arm will receive combination therapy with PegIntron and Rebetol for 48 weeks; then will enter a 24-week post-treatment Follow-up. Subjects who have detectable Hepatitis C Virus-RNA at Treatment Week 24 will discontinue treatment and enter Follow-up.

03

Conditions studied

  • Hepatitis C, Chronic
  • Liver Cirrhosis
04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients with compensated hepatic cirrhosis secondary to chronic who would meet all the inclusion criteria below and would not interfere with any of the exclusion criteria below.

  • Patients (regardless of gender) who can take measures from date of to the end of follow-up
  • Patients who meet all the criteria below in the test/observation/ investigation in 30 days before the beginning of treatment.

    • Patients with quantitative HCV-RNA (+)
    • > 40 IU/L
    • Patients who are classified as Classification A, and who do not have ascites or hepatic encephalopathy
    • \<=3.0 seconds prolonged, total \<= 1.5 mg/dL or direct bilirubin \<= 0.7 mg/dL, Albumin >= 3.0 g/dL
    • AFP within normal limits, AFP-L3 \<= 10%,PIVKA-II \<= 100 mAU/mL
    • Serum creatinine \<= , >= 51 mL/minute
    • Patients with fasting blood glucose \< 110 mg/dL.
    • Thyroid-stimulating hormone within normal limits
    • level >= 12 g/dL,leukocyte count >= 3,000/mm3, >= 1,500 /mm3, count >= 80,000/mm3
  • Patients who weighs more than 40 kg and not more than 100 kg within 60 days prior to registration
  • Patients who were diagnosed with liver cirrhosis (fibrosis score: F4) based on the liver performed within a year prior to registration and is able to provide with liver tissue sample.
  • Patients who between the ages of 20 and 70 years at time of informed consent who can give written informed consent
  • Patients who can be hospitalized at least for 14 days from the initiation of treatment.

Exclusion criteria

Exclusion Criteria:

  • Patients who have been administered pegylated interferon or ribavirin in the past.
  • Patients who had previously received treatment with IFN for whom at least 90 days have not elapsed since the end of previous treatment by the time of registration in the study
  • Patients who have received treatment within 14 days prior to registration with the injectable preparations containing glycyrrhizin/cysteine/glycyron (Stronger Neo-Minophagen C, etc.), or shosaikoto
  • Patients who have had antiviral drug or antitumor drug, or immune regulation therapy (including administration, radiation therapy) within 90 days prior to registration. [except for topical application and external drug]
  • Patients who have been administered any study drug within 180 days prior to registration.
  • Patients who meet the following criteria in the screening test

    • HBs antigen positive
    • antinuclear antibody >= 320 times
  • Patients with or who have a history of primary biliary cirrhosis, hepatic failure, hepatocellular carcinoma.
  • Patients with other etiologies of liver disease such as , alcoholic and drug-induced liver diseases
  • Patients with or who have a history of decompensated cirrhosis with following disorder. Ascites, jaundice, bleeding varices, esophageal and/or gastric varices which needs treatment, hepatic encephalopathy, and spontaneous bacterial peritonitis.
  • Patients with hemophilia
  • Patients with or who have a history of neuropsychiatry disorder such as depression.
  • Patients with or who have a history of epileptic seizures requiring treatment
  • Patients with or who have a history of angina pectoris, heart failure, myocardial infarction, uncontrollable hypertension (diastolic blood pressure: equal to or more than 110mmHg) or arrhythmia which needs treatment.
  • Patients with chronic pulmonary disease
  • Patients with or who have a history of autoimmune disease (Crohn's disease, ulcerative colitis, chronic rheumatoid arthritis, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, autoimmune hemolytic anemia, scleroderma, etc).
  • Patients with Hemoglobinopathies (thalassaemia, sickle cell anemia)
  • Patients with malignant tumors
  • Patients with organ transplants (other than cornea and hair transplant).
  • Patients with a history of to interferon preparations, biological products such as vaccine, or nucleoside analogs
  • Female patients who are pregnant or nursing (male patients with partner who are pregnant), and for whom pregnancy cannot be ruled out by serum HCG test conducted during the screening period
  • Patients with specific reaction to PEG-IFNα-2b in prick test conducted before the initiation of treatment(Only PEG/R group)
  • Other patients judged by the investigator (sub-investigator) to be inappropriate for inclusion in this study
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Treatment Arm

    Biological: PegIntron (peginterferon alfa-2b; SCH 54031) · Drug: Rebetol (ribavirin; SCH 18908)

  • No intervention
    Control Arm

Interventions

06

What researchers measure

Primary outcomes

  1. Sustained virologic response rate, defined as the proportion of subjects with undetectable HCV-RNA at 24-week post-treatment follow-up

    Time frame: Measured at 24 weeks post-treatment

Secondary outcomes

  1. Rate of subject with undetectable HCV-RNA at the end of treatment (or at discontinuation of treatment)

    Time frame: Measured at the end of treatment (or at discontinuation of treatment)

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2003, a primary completion of May 2006 and a completion of May 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2008
First posted
Dec 19, 2008
Start
Feb 2003
Primary completionActual
May 2006
CompletionActual
May 2006
Last update
Mar 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00811967
Responsible party
Sponsor
First posted
Dec 19, 2008
Start date
Feb 2003
Primary completion
May 2006
Completion
May 2006
Last update
Mar 13, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Peginterferon alfa-2b · Ribavirin

Start the discussion